Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 152Neoplasms 108Carcinoma, Non-Small-Cell Lung 83Colorectal Neoplasms 81Prostatic Neoplasms 80Lung Neoplasms 71Leukemia, Myeloid, Acute 48Carcinoma, Hepatocellular 48Pancreatic Neoplasms 45Neoplasm Metastasis 39Multiple Myeloma 37Recurrence 34Triple Negative Breast Neoplasms 29Squamous Cell Carcinoma of Head and Neck 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Melanoma 27Glioblastoma 27Head and Neck Neoplasms 25Brain Neoplasms 25Uterine Cervical Neoplasms 24Stomach Neoplasms 24Rectal Neoplasms 24Ovarian Neoplasms 24Small Cell Lung Carcinoma 22Carcinoma, Renal Cell 20Lymphoma, B-Cell 19Lymphoma, Follicular 18Lymphoma 18Endometrial Neoplasms 18Glioma 17

Interventions

Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Hemangioma × 90 days × Clear all
NCT07477548 2026-03-17

A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies

Yonsei University

Phase 2 Not yet recruiting
67 enrolled

Arteriovenous Malformations, Hemangioendothelioma, Hemangioma, Lymphangioma, Nevus, Vascular Malformations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡